Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dexmedetomidine Effects on Basal Ganglia Activity in PD
NCT02982512Phase 4Unknown
- Sponsor
- Universidad de Navarra
- Start
- May 2017
- Primary completion
- Sep 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of dexmedetomidine in Parkinson's disease (PD) (2 arms), sponsored by Universidad de Navarra. Primary endpoint: Beta activity (15-35 Hz). Status: unknown.
02
Drugs
dexmedetomidine
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on NCT02982512.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02982512.